Lilly's Zepbound and Taltz improve psoriasis symptoms, drive weight loss in study

Eli Lilly announced on Wednesday that the combined use of its weight-loss drug Zepbound with psoriasis treatment Taltz demonstrated improved outcomes in a late-stage clinical study, potentially offering a dual benefit for patients with both conditions. The pharmaceutical giant's findings revealed that patients receiving both medications experienced significantly greater reduction in psoriasis symptoms compared to those using Taltz alone. Additionally, the combination therapy led to notable weight loss, making it a promising option for individuals struggling with both psoriasis and obesity. The late-stage study, which has not yet been published in a peer-reviewed journal, represents a potential new market opportunity for Eli Lilly as pharmaceutical companies increasingly explore combination therapies for chronic conditions.